title: Major response to imatinib mesylate in KIT-mutated melanoma.
authors.affiliation: The Melanoma Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Philip
authors.initials: P
authors.lastname: Friedlander
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Corless
authors.forename: Michael C
authors.initials: MC
authors.lastname: Heinrich
authors.forename: Suzanne
authors.initials: S
authors.lastname: Mac Rae
authors.forename: Andrea
authors.initials: A
authors.lastname: Kruse
authors.forename: Jyothi
authors.initials: J
authors.lastname: Jagannathan
authors.forename: Annick D
authors.initials: AD
authors.lastname: Van den Abbeele
authors.forename: Elsa F
authors.initials: EF
authors.lastname: Velazquez
authors.forename: George D
authors.initials: GD
authors.lastname: Demetri
authors.forename: David E
authors.initials: DE
authors.lastname: Fisher
mesh_terms: D000368:Aged; D000714:Anastomosis, Surgical / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009366:Neoplasm Seeding; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit